Efficacy of febuxostat on hyperuricemia and estimated glomerular filtration rate in patients with non-dialysis stage 3/4 chronic kidney disease and assessment of cardiac function: a 12-month interventional study
In the interventional group, febuxostat was well-tolerated and demonstrated a reduction in SUA associated with an increase in eGFR. This slowed down the progression of renal disease in patients with non-dialysis stage 3/4 CKD and improved cardiac function.
Authors
- Fan Yang (ORCID: https://orcid.org/0000-0003-3680-0547)
- Disheng Wang
- Dong Sun (ORCID: https://orcid.org/0000-0002-4546-404X)
- Yasir Waheed (ORCID: https://orcid.org/0000-0002-5789-4215)
- Karthick Kumaran Munisamy Selvam
- Jie Liu (ORCID: https://orcid.org/0000-0003-1398-5411)
- Shifaa Almayahe
Institutions
- Xuzhou Medical College (CN)
- University Of Fallujah (IQ)
Publication Details
- Journal
- Frontiers in Nephrology
- Published
- 2025-03-26
- DOI
- https://doi.org/10.3389/fneph.2025.1526182
- Citations
- 5
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 7.15
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Jiangsu Provincial Commission of Health and Family Planning